The eating disorders (DCA) are complex systemic diseases with high social impact, which tend to become chronic with significant medical and psychiatric comorbidities. The literature data showed that there is good evidence to suggest the use of SSRIs, particularly at high doses of fluoxetine, in the treatment of BN reducing both the crisis of binge that the phenomena compensates and reducing the episodes of binge in patients with BED in the short term. Also, the topiramate (an AED) showed a good effectiveness in reducing the frequency and magnitude of episodes of binge with body weight reduction, both in the BN that is in the therapy of BED. To date, modest data support the use of low doses of second-generation antipsychotics in an attempt to reduce the creation of polarized weight and body shapes, the obsessive component, and anxiety in patients with AN. Data in the literature on long-term drug treatment of eating disorders are still very modest. It is essential to remember that the pharmacotherapy has, however, a remarkable efficacy in treating psychiatric disorders that occur in comorbidity with eating disorders, such as mood disorders, anxiety, insomnia, and obsessive-compulsive personality disorders and behavior. 1. Introduction The eating the disorders (ED) include several pathological conditions such as anorexia nervosa (AN), bulimia nervosa (BN), the binge eating disorder (BED), and eating disorders not otherwise specified [1]. DCA are important diseases with high social impact, affecting mainly the younger members of the population with a clinical course characterized by frequent exacerbations or relapses tending to become chronic, significant sequelae medical and psychiatric comorbidities that make these diseases among the most debilitating and fatal within psychiatric [2]. The lifetime prevalence of these diseases is currently estimated at 0.6% for AN, 1% for BN, and about 3% for BED [3]. The treatment of the DCA is substantially multidimensional and includes psychotherapy, nutritional rehabilitation, and drug treatment, both to control the core symptoms of DCA and to treat frequent psychiatric comorbidities, extremely frequent in this group of pathologies [4]. Basically all the drugs introduced in the clinic were tested in an attempt to treat the clinical manifestations of eating disorders, although often with contradictory results. Among other issues, it is important to note that, with the exception of fluoxetine for the treatment of bulimia nervosa (BN), nowadays, no drug has been approved by the national and international regulatory
References
[1]
American Psychiatric Association (APA), Diagnostic and Statistic Manual of Mental Disorders, APA, Waschington, DC, USA, 4th edition, 2000.
[2]
A. Capasso, C. Petrella, and W. Milano, “Recent clinical aspects of eating disorders,” Reviews on Recent Clinical Trials, vol. 4, no. 1, pp. 63–69, 2009.
[3]
J. I. Hudson, E. Hiripi, H. G. Pope Jr., and R. C. Kessler, “The prevalence and correlates of eating disorders in the national comorbidity survey replication,” Biological Psychiatry, vol. 61, no. 3, pp. 348–358, 2007.
[4]
J. Treasure, A. M. Claudino, and N. Zucker, “Eating disorders,” The Lancet, vol. 375, no. 9714, pp. 583–593, 2010.
[5]
National Institute for Clinic Excellence, “Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimis nervosa and related disorders,” London, UK, Clinical guideline Number 9. 2004.
[6]
M. Aigner, J. Treasure, W. Kaye, and S. Kasper, “World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders,” World Journal of Biological Psychiatry, vol. 12, no. 6, pp. 400–443, 2011.
[7]
American Psychiatric Association (APA), “Practice guidelines for the treatment of patients with eating disorders,” in Practice Guidelines for the Treatment of Psychiatric Disorders, 3th edition, 2006.
[8]
P. J. Hay and A. M. Claudino, “Clinical psychopharmacology of eating disorder: a research update,” International Journal of Neuropsychopharmacology, vol. 6, pp. 1–14, 2011.
[9]
R. F. McKnight and R. J. Park, “Atypical antipsychotics and anorexia nervosa: a review,” European Eating Disorders Review, vol. 18, no. 1, pp. 10–21, 2010.
[10]
P. S. Powers and C. Santana, “Available pharmacological treatments for anorexia nervosa,” Expert Opinion on Pharmacotherapy, vol. 5, no. 11, pp. 2287–2292, 2004.
[11]
W. Vandereycken, “Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride,” British Journal of Psychiatry, vol. 144, no. 3, pp. 288–292, 1984.
[12]
M. F. Flament, H. Bissada, and W. Spettigue, “Evidence-based pharmacotherapy of eating disorders,” International Journal of Neuropsychopharmacology, vol. 15, no. 2, pp. 189–207, 2012.
[13]
N. Mondraty, C. Laird Birmingham, S. Touyz, V. Sundakov, L. Chapman, and P. Beumont, “Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa,” Australasian Psychiatry, vol. 13, no. 1, pp. 72–75, 2005.
[14]
F. Brambilla, C. S. Garcia, S. Fassino et al., “Olanzapine therapy in anorexia nervosa: psychobiological effects,” International Clinical Psychopharmacology, vol. 22, no. 4, pp. 197–204, 2007.
[15]
H. Bissada, G. A. Tasca, A. M. Barber, and J. Bradwejn, “Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial,” American Journal of Psychiatry, vol. 165, no. 10, pp. 1281–1288, 2008.
[16]
P. S. Powers and H. Bruty, “Pharmacotherapy for eating disorders and obesity,” Child and Adolescent Psychiatric Clinics of North America, vol. 18, no. 1, pp. 175–187, 2009.
[17]
S. L. McElroy and A. I. Guerdjikova, “Current pharmacotherapy options for bulimia nervosa and binge eating disorder,” Expert Opinion on Pharmacotherapy, vol. 13, pp. 2015–2026, 2012.
[18]
D. Mischoulon, K. T. Eddy, A. Keshaviah et al., “Depression and eating disorders: treatment and course,” Journal of Affective Disorders, vol. 130, no. 3, pp. 470–477, 2011.
[19]
F. Brambilla, “Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment,” CNS Drugs, vol. 15, no. 2, pp. 119–136, 2001.
[20]
K. A. Halmi, E. Eckert, T. J. LaDu, and J. Cohen, “Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline,” Archives of General Psychiatry, vol. 43, no. 2, pp. 177–181, 1986.
[21]
T. Walsch and A. S. Kaplan, “Fluoxetina after weight restoration in anorexia nervosa,” Journal of the American Medical Association, vol. 295, pp. 2605–2612, 2006.
[22]
W. H. Kaye, “Neurobiology of anorexia nervosa purdue ingestive behavior research center symposium influences on eating and body weight over the lifespan: children and adolescents,” Physiology & Behavior, vol. 94, pp. 121–135, 2008.
[23]
A. Capasso, C. Petrella, and W. Milano, “Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders,” Current Clinical Pharmacology, vol. 4, no. 1, pp. 78–83, 2009.
[24]
J. Bacaltchuk and P. Hay, “Antidepressants versus placebo for people with bulimia nervosa,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD003391, 2001.
[25]
W. Milano, C. Petrella, C. Sabatino, and A. Capasso, “Treatment of bulimia nervosa with sertraline: a randomized controlled trial,” Advances in Therapy, vol. 21, no. 4, pp. 232–237, 2004.
[26]
W. Milano, C. Siano, C. Putrella, and A. Capasso, “Treatment of Bulimia nervosa with fluvoxamine: a randomized controlled trial,” Advances in Therapy, vol. 22, no. 3, pp. 278–283, 2005.
[27]
V. Martiadis, E. Castaldo, P. Monteleone, and M. Maj, “The role of psychopharmacotherapy in the treatment of eating disorders,” Clinical Neuropsychiatry, vol. 4, no. 2, pp. 51–60, 2007.
[28]
S. J. Romano, K. A. Halmi, N. P. Sarkar, S. C. Koke, and J. S. Lee, “A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment,” American Journal of Psychiatry, vol. 159, no. 1, pp. 96–102, 2002.
[29]
S. C. Stefano, J. Bacaltchuk, S. L. Blay, and J. C. Appolinário, “Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis,” Eating Behaviors, vol. 9, no. 2, pp. 129–136, 2008.
[30]
D. L. Reas and C. M. Grilo, “Review and meta-analysis of pharmacotherapy for binge-eating disorder,” Obesity, vol. 16, no. 9, pp. 2024–2038, 2008.
[31]
A. I. Guerdjikova, S. L. McElroy, E. L. Winstanley et al., “Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial,” International Journal of Eating Disorders, vol. 45, no. 2, pp. 281–289, 2012.
[32]
J. C. Appolinario, J. Bacaltchuk, R. Sichieri et al., “A randomized, double-blind, placebo-controlled study of sibutramina in the treatment of binge eating disorder,” Archives of General Psychiatry, vol. 60, no. 11, pp. 1109–1116, 2003.
[33]
W. Milano, C. Petrella, A. Casella, A. Capasso, S. Carrino, and L. Milano, “Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study,” Advances in Therapy, vol. 22, no. 1, pp. 25–31, 2005.
[34]
R. L. Horne, J. M. Ferguson, H. G. Pole Jr. et al., “Treatment of bulimia with bupropion: a multicenter controlled trial,” Journal of Clinical Psychiatry, vol. 49, no. 7, pp. 262–266, 1988.
[35]
O. Gao and T. L. Horvast, “Neuronal control of henergy homeostasis,” FEBS Letters, vol. 582, pp. 132–141, 2008.
[36]
B. Meister, “Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight,” Physiology & Behavior, vol. 92, no. 1-2, pp. 263–271, 2007.
[37]
S. L. McElroy, A. I. Guerdjikova, B. Martens, P. E. Keck Jr., H. G. Pope, and J. I. Hudson, “Role of antiepileptic drugs in the management of eating disorders,” CNS Drugs, vol. 23, no. 2, pp. 139–156, 2009.
[38]
D. W. Hedges, F. W. Reimherr, S. P. Hoopes et al., “Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial—part 2: improvement in psychiatric measures,” Journal of Clinical Psychiatry, vol. 64, no. 12, pp. 1449–1454, 2003.
[39]
S. P. Hoopes, F. W. Reimherr, D. W. Hedges et al., “Treatment of bulimia nervosa with topiramato in a randomized, double-blind, placebo controlled trial—part 1: improvement in psychiatric measures,” Journal of Clinical Psychiatry, vol. 64, no. 11, pp. 1335–1341, 2003.
[40]
C. Nickel, K. Tritt, M. Muehlbacher et al., “Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial,” International Journal of Eating Disorders, vol. 38, no. 4, pp. 295–300, 2005.
[41]
S. L. McElroy, J. I. Hudson, J. A. Capece, K. Beyers, A. C. Fisher, and N. R. Rosenthal, “Topiramato for treatment of binge eating disorder associated ad obesity: a placebo,” Biological Psychiatry, vol. 61, no. 9, pp. 1039–1048, 2007.
[42]
V. Ricca, G. Castellini, C. Lo Sauro, C. M. Rotella, and C. Faravelli, “Zonisamide combined with cognitive behavioral therapy in binge eating disorder: a one-year follow-up study,” Psychiatry, vol. 6, no. 11, pp. 23–28, 2009.
[43]
A. Golay, A. Laurent-Jaccard, F. Habicht et al., “Effect of orlistat in obese patients with binge eating disorder,” Obesity Research, vol. 13, no. 10, pp. 1701–1708, 2005.
[44]
S. L. McElroy, A. Guerdjikova, R. Kotwal et al., “Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 68, no. 3, pp. 390–398, 2007.
[45]
M. Cuzzolaro, “Il trattamento dei disturbi del comportamento alimentare,” Noos, vol. 1, pp. 49–66, 2003.
[46]
L. R. Levine, H. G. Pope Jr., G. G. Enas et al., “Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo- controlled, double-blind trial,” Archives of General Psychiatry, vol. 49, no. 2, pp. 139–147, 1992.
